Journal of International Obstetrics and Gynecology ›› 2021, Vol. 48 ›› Issue (6): 610-614.doi: 10.12280/gjfckx.20210102
• Research on Gynecological Malignancies:Review • Previous Articles Next Articles
Received:
2021-01-27
Published:
2021-12-15
Online:
2021-12-30
Contact:
KONG Wei-min
E-mail:kwm1967@ccmu.edu.cn
LIN Yu-xuan, KONG Wei-min. Research Progress of the Quality of Life of Patients with Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 610-614.
Add to citation manager EndNote|Ris|BibTeX
[1] |
Berek JS, Kehoe ST, Kumar L, et al. Cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet, 2018,143(Suppl 2):59-78. doi: 10.1002/ijgo.12614.
doi: 10.1002/ijgo.12614 |
[2] |
Lutgendorf SK, Shinn E, Carter J, et al. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach[J]. Gynecol Oncol, 2017,146(1):101-108. doi: 10.1016/j.ygyno.2017.05.008.
doi: S0090-8258(17)30846-6 pmid: 28527672 |
[3] |
The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties[J]. Soc Sci Med, 1998,46(12):1569-1585. doi: 10.1016/s0277-9536(98)00009-4.
doi: 10.1016/s0277-9536(98)00009-4 |
[4] |
von Gruenigen VE, Huang HQ, Cella D, et al. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2018,150(1):119-126. doi: 10.1016/j.ygyno.2018.05.017.
doi: S0090-8258(18)30904-1 pmid: 29778506 |
[5] |
Kim SI, Lee Y, Lim MC, et al. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women[J]. J Gynecol Oncol, 2015,26(2):148-154. doi: 10.3802/jgo.2015.26.2.148.
doi: 10.3802/jgo.2015.26.2.148 pmid: 25686396 |
[6] |
Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial[J]. Lancet Oncol, 2018,19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4.
doi: 10.1016/S1470-2045(18)30333-4 |
[7] |
Koole SN, Kieffer JM, Sikorska K, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer[J]. Eur J Surg Oncol, 2021,47(1):101-107. doi: 10.1016/j.ejso.2019.05.006.
doi: 10.1016/j.ejso.2019.05.006 pmid: 31128948 |
[8] |
Zhou Y, Cartmel B, Gottlieb L, et al. Randomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women′s Activity and Lifestyle Study in Connecticut (WALC)[J]. J Natl Cancer Inst, 2017,109(12):djx072. doi: 10.1093/jnci/djx072.
doi: 10.1093/jnci/djx072 |
[9] |
Guy H, Walder L, Fisher M. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States[J]. Pharmacoeconomics, 2019,37(3):391-405. doi: 10.1007/s40273-018-0745-z.
doi: 10.1007/s40273-018-0745-z |
[10] |
Coleman RL, Spirtos NM, Enserro D, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer[J]. N Engl J Med, 2019,381(20):1929-1939. doi: 10.1056/NEJMoa1902626.
doi: 10.1056/NEJMoa1902626 |
[11] |
Wright JD, Hou JY, Burke WM, et al. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer[J]. Obstet Gynecol, 2016,127(6):985-991. doi: 10.1097/AOG.0000000000001436.
doi: 10.1097/AOG.0000000000001436 pmid: 27159764 |
[12] |
Holliday CM, Morte M, Byrne JM, et al. Experience and Expectations of Ovarian Cancer Patients in Australia[J]. J Oncol, 2018,2018:7863520. doi: 10.1155/2018/7863520.
doi: 10.1155/2018/7863520 |
[13] |
Moss JL, Murphy J, Filiaci VL, et al. Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants[J]. Support Care Cancer, 2019,27(2):531-538. doi: 10.1007/s00520-018-4340-9.
doi: 10.1007/s00520-018-4340-9 |
[14] |
Medina-Franco H, Mejía-Fernández L. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages[J]. Chin Clin Oncol, 2018,7(6):57. doi: 10.21037/cco.2018.06.10.
doi: 10.21037/cco.2018.06.10 pmid: 30180749 |
[15] |
Chan JK, Brady MF, Penson RT, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer[J]. N Engl J Med, 2016,374(8):738-748. doi: 10.1056/NEJMoa1505067.
doi: 10.1056/NEJMoa1505067 |
[16] |
Kumar S, Long J, Kehoe S, et al. Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer, 2019,29(8):1285-1291. doi: 10.1136/ijgc-2018-000125.
doi: 10.1136/ijgc-2018-000125 |
[17] |
Holman DA. Fertility Preservation in Gynecologic Cancer[J]. Semin Oncol Nurs, 2019,35(2):202-210. doi: 10.1016/j.soncn.2019.02.007.
doi: 10.1016/j.soncn.2019.02.007 |
[18] |
Bauersfeld SP, Kessler CS, Wischnewsky M, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study[J]. BMC Cancer, 2018,18(1):476. doi: 10.1186/s12885-018-4353-2.
doi: 10.1186/s12885-018-4353-2 pmid: 29699509 |
[19] |
Wang R, Sun Q, Wang F, et al. Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2019,9:730. doi: 10.3389/fonc.2019.00730.
doi: 10.3389/fonc.2019.00730 |
[20] |
Morrison V, Spencer LH, Totton N, et al. Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial[J]. Int J Gynecol Cancer, 2018,28(2):401-411. doi: 10.1097/IGC.0000000000001179.
doi: 10.1097/IGC.0000000000001179 pmid: 29324539 |
[21] |
Rinninella E, Fagotti A, Cintoni M, et al. Nutritional Interventions to Improve Clinical Outcomes in Ovarian Cancer: A Systematic Review of Randomized Controlled Trials[J]. Nutrients, 2019,11(6):1404. doi: 10.3390/nu11061404.
doi: 10.3390/nu11061404 |
[22] |
Jones TL, Sandler CX, Spence RR, et al. Physical activity and exercise in women with ovarian cancer: A systematic review[J]. Gynecol Oncol, 2020,158(3):803-811. doi: 10.1016/j.ygyno.2020.06.485.
doi: 10.1016/j.ygyno.2020.06.485 |
[23] |
Zhang Q, Li F, Zhang H, et al. Effects of nurse-led home-based exercise & cognitive behavioral therapy on reducing cancer-related fatigue in patients with ovarian cancer during and after chemotherapy: A randomized controlled trial[J]. Int J Nurs Stud, 2018,78:52-60. doi: 10.1016/j.ijnurstu.2017.08.010.
doi: S0020-7489(17)30188-8 pmid: 28939343 |
[24] |
Iyer NS, Cartmel B, Friedman L, et al. Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity[J]. Cancer, 2018,124(9):1929-1937. doi: 10.1002/cncr.31239.
doi: 10.1002/cncr.31239 |
[25] |
Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial[J]. Lancet Oncol, 2018,19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7.
doi: S1470-2045(18)30343-7 pmid: 30026002 |
[26] |
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011,365(26):2473-2483. doi: 10.1056/NEJMoa1104390.
doi: 10.1056/NEJMoa1104390 |
[27] |
Bielik J, Bystricky B, Hoffmannova K, et al. Quality of life and ability to work in ovarian cancer patients in Slovakia[J]. Neoplasma, 2020,67(2):389-393. doi: 10.4149/neo_2020_190401N285.
doi: 10.4149/neo_2020_190401N285 pmid: 31986888 |
[28] |
Colombo N, Lorusso D, Scollo P. Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future[J]. Int J Gynecol Cancer, 2017,27(6):1134-1140. doi: 10.1097/IGC.0000000000001023.
doi: 10.1097/IGC.0000000000001023 |
[29] |
Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer[J]. Expert Rev Anticancer Ther, 2017,17(12):1147-1158. doi: 10.1080/14737140.2017.1398088.
doi: 10.1080/14737140.2017.1398088 |
[30] |
Iorio GC, Martini S, Arcadipane F, et al. The role of radiotherapy in epithelial ovarian cancer: a literature overview[J]. Med Oncol, 2019,36(7):64. doi: 10.1007/s12032-019-1287-8.
doi: 10.1007/s12032-019-1287-8 |
[1] | CHEN Xiu-jie, WANG Ya-nan, CHENG Qian-qian, ZHANG Ji-wen, SONG Dian-rong. Lesion Resection Combined with Skin Flap Transplantation in the Treatment of Recurrent Vulvar Paget′s Disease: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2025, 52(2): 237-240. |
[2] | BAI Yao-jun, WANG Si-yao, LING Fei-fei, ZHANG Sen-huai, LI Hong-li, LIU Chang. Progress of Trop-2 and Targeted Trop-2 Antibody-Coupled Drugs in Gynecological Malignant Tumors [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 1-7. |
[3] | ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue. Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 19-22. |
[4] | LI Nan, PENG Er-xuan, LIU Feng-hua. Clinical Analysis of 20 Cases of Brain Metastasis from Ovarian Epithelial Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 23-27. |
[5] | JIA Yan-feng, WU Zhen-zhen, WANG Wei-hong, WANG Yue-yuan, LI Juan. A Case of Primary Ovarian Adenosquamous Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 32-36. |
[6] | SONG Li-fang, WU Zhen-zhen, MAO Bao-hong, ZHAO Xiao-li, LIU Qing. A Case of Isolated Lymph Node Metastasis from Ovarian Cancer to the Inguinal Region [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 37-41. |
[7] | LUO Na, CHEN Yan. A Case of Recurrent Uterine Smooth Muscle Tumor of Uncertain Malignant Potential Underwent Hysterectomy after Hysteroscopic Lesion Resection [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 42-45. |
[8] | LIU Si-min, LI Hong-li, GUO Xi, HU Ya-li, YANG Yong-xiu. Late Pregnancy with Ovarian Serous Cystadenoma Pedicle Torsion: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 632-635. |
[9] | HUANG Mo-ya, ZHAO Ya-qian, HE Yin-fang. Progress in the Diagnosis and Treatment of Pregnancy Complicated by Krukenberg Tumor [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 531-535. |
[10] | ZHANG Jian-nan, GUO Xin, GUO Nan, NING Wen-ting, YU Hong-xin, SHANG Hai-xia. Application of Microfluidic Technology in Ovarian Cancer Disease Modeling, Drug Evaluation, and Precision Medicine [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 560-565. |
[11] | JIN Xiao-lei, XU Fei-xue. Five Cases of Diagnosis and Treatment of Ovarian Brenner Tumors [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 578-583. |
[12] | CHEN Zhi-wei, LIU Lin. A Case of Ovarian Malignant Tumor with SMARCA4 Gene Deletion [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 584-587. |
[13] | MING Yang, HU Yuan-yuan, FENG Tong-fu. A Case of Recurrent Cellular Uterine Leiomyoma with Peritoneal Dissemination after Surgery [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 593-596. |
[14] | SU Hai-qi, LI Lei. Advances in Methylation Detection for Ovarian Cancer Screening and Diagnosis [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 366-369. |
[15] | ZHANG Jing-yi, LIU Dong-zhe, CHEN Xiu-hui. Research Advances of Exosomes in Angiogenesis of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 370-374. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||